8-K: STAAR Surgical Reports Weak Q4 and Fiscal Year 2024 Results Amid China Slowdown, Provides Cautious 2025 Outlook

STAAR Surgical's Q4 and fiscal year 2024 results were impacted by weak macroeconomic conditions in China, overshadowing growth in other regions, and the company anticipates lower demand in China for fiscal year 2025.

Summary

• STAAR Surgical reported net sales of $49.0 million for Q4 2024, a decrease from $76.3 million in the prior year quarter.
• ICL sales were $46.9 million, with China ICL sales at $7.5 million and ICL sales excluding China at $39.5 million, a 17% increase year-over-year.
• Fiscal year 2024 net sales were $313.9 million, down from $322.4 million in the prior year.
• ICL sales for fiscal year 2024 totaled $312.5 million, with China ICL sales at $161.0 million and ICL sales excluding China at $151.6 million, a 13% increase year-over-year.
• The company reported a net loss of $(34.2) million or $(0.69) per diluted share for Q4 2024, compared to a net income of $7.8 million or $0.16 per diluted share in the prior year quarter.
• For fiscal year 2024, the net loss was $(20.2) million or $(0.41) per diluted share, compared to a net income of $21.3 million or $0.43 per diluted share in the prior year.
• Adjusted EBITDA for fiscal year 2024 was $23.2 million or $0.47 per share, compared to $56.8 million or $1.15 per share in the prior year.
• The company expects ICL sales excluding China to be approximately $165 million to $175 million in fiscal year 2025, representing 9% to 15% growth.
• China ICL sales are expected to be less than $5 million in the first half of 2025 and approximately $75 million to $125 million in the second half.
• The company anticipates an Adjusted EBITDA loss of approximately $(30) million per quarter in the first half of 2025 and an Adjusted EBITDA gain range of approximately $5 million to $22.5 million per quarter in the second half, resulting in a full-year Adjusted EBITDA loss range of approximately $(50) million to $(15) million.
• STAAR expects to end fiscal year 2025 with cash, cash equivalents, and investments available for sale of approximately $150 million to $175 million.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to the significant decline in financial performance, particularly in China, and the lowered outlook for 2025. However, the company's strong balance sheet and growth in other regions provide some positive aspects.

Positives

• ICL sales excluding China showed strong growth, increasing by 17% in Q4 2024 and 13% for the full year, demonstrating the global demand for STAAR's products outside of China.
• The company has a strong balance sheet with $230.5 million in cash, cash equivalents, and investments available for sale at the end of fiscal year 2024.
• STAAR is taking proactive measures to address the challenges in China, including collaborating with distributors to manage inventory levels and positioning the company for a future rebound.
• The company is making market-building investments in surgeon education, technology, and commercial teams to drive ICL adoption.
• STAAR expects to sustain double-digit growth across global markets outside of China in 2025.

Negatives

• Net sales decreased in both Q4 2024 and fiscal year 2024, primarily due to a significant decline in China revenue.
• The company reported a net loss of $(34.2) million in Q4 2024 and $(20.2) million for fiscal year 2024, a significant downturn compared to the previous year's net income.
• Gross profit margin decreased in both Q4 and fiscal year 2024, attributed to factors including cost of sales related to China shipments and manufacturing expenses.
• STAAR anticipates a challenging first half of fiscal year 2025 with continued weakness in China.
• The company is implementing cost-cutting measures, including lowering production output and reducing operating expenses, which will impact headcount and discretionary spend.
• STAAR no longer expects to achieve its Vision 2026 Target Sales and Operating Model, originally announced on September 14, 2023.

Risks

• Weak macroeconomic conditions and consumer confidence in China are negatively impacting demand for ICLs.
• Elevated inventory levels in China may take time to resolve, further delaying revenue recognition.
• Fluctuations in foreign currency exchange rates could impact financial results.
• The company's reliance on independent distributors in international markets poses a risk to sales and distribution.
• Global economic conditions and international trade disputes could negatively affect the company's performance.
• The company's ability to achieve its financial projections for fiscal year 2025 is subject to various assumptions and uncertainties, including the overall refractive procedure volumes in different regions.

Future Outlook

The company expects ICL sales excluding China to grow by 9% to 15% in fiscal year 2025, while China ICL sales are expected to be lower in the first half of the year with a potential rebound in the second half. The company anticipates an Adjusted EBITDA loss for the full year 2025.

Management Comments

• STAAR's fiscal 2024 results reflect fluctuating demand in China, which more than offset the strong performance across our other regions, said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical.
• Outside of China, we expect to sustain double-digit growth across our global markets in 2025 as demand for our ICL technology continues to outpace the refractive market overall, according to Mr. Frinzi.
• We have built up a strong balance sheet that provides STAAR with the resiliency to face these macroeconomic challenges, which we believe are transitory, stated Mr. Frinzi.

Industry Context

The announcement highlights the impact of macroeconomic conditions in China on the refractive surgery market, while also noting the continued growth potential of ICL technology in other regions. This suggests that companies in this space are susceptible to regional economic fluctuations and must diversify their market presence.

Comparison to Industry Standards

• While specific competitor data isn't provided, the report mentions that STAAR's ICL sales growth outside of China is outpacing the overall refractive market, suggesting a competitive advantage in those regions.
• The company's challenges in China reflect broader economic trends affecting consumer discretionary spending, which may be impacting other players in the market as well.
• The company's gross margin of 76.3% is a key indicator of profitability compared to industry averages, and the company believes it has the potential to achieve 80%+ gross margin.

Stakeholder Impact

• Shareholders will be impacted by the decreased financial performance and lowered outlook.
• Employees may be affected by the cost-cutting measures, including potential headcount reductions.
• Customers and patients may experience changes in product availability or service levels due to the company's adjustments to production and operations.
• Suppliers and creditors may be impacted by the company's efforts to manage working capital and reduce capital expenditures.

Next Steps

• The company will manage its working capital and implement cost-cutting measures.
• STAAR intends to lower production output, decrease capital expenditures, and make targeted reductions to operating expenses.
• The company will continue to make market-building investments in surgeon education, technology and our commercial teams and strategies to drive ICL adoption.

Key Dates